Anglo-Swedish Medicinal Chemistry - second symposium.
Sarabu
Ramakanth
R
Hoffmann-La Roche Inc, Nutley, NJ 07110-1109, USA. ramakanth.sarabu@roche.com
D000818:Animals; D001549:Benzamides; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D020536:Enzyme Activators / Q000627:therapeutic use; D005941:Glucokinase / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors; D012958:Societies, Scientific; D013548:Sweden; D013844:Thiazoles / Q000627:therapeutic use; D006113:United Kingdom; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
D001549:Benzamides; D020536:Enzyme Activators; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C476008:RO-28-0450; D013844:Thiazoles; D000068877:Imatinib Mesylate; D005941:Glucokinase; D017526:Receptor, IGF Type 1; D019061:src-Family Kinases; D048031:JNK Mitogen-Activated Protein Kinases